1-4 of 4
Satoru Kitazono
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, Yutaka Fujiwara, Shigenobu Suzuki, Noriko Yanagitani, Atsushi Horiike, Satoru Kitazono, Fumiyoshi Ohyanagi, Toshihiko Doi, Yasutoshi Kuboki, Akihito Kawazoe, Kohei Shitara, Izumi Ohno, Udai Banerji, Raghav Sundar, Shuichi Ohkubo, Elizabeth M. Calleja, Makoto Nishio
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 531–540.
https://doi.org/10.1158/1535-7163.MCT-18-0831
Published: 01 March 2019
View article titled, First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors in another window
Journal Articles

Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

Akihiko Shimomura, Atsushi Horiike, Yuichi Tambo, Fumiyoshi Ohyanagi, Noriko Yanagitani, Satoru Kitazono, Yutaka Fujiwara, Yuko Tanabe, Shuichi Ohkubo, Noboru Yamamoto, Makoto Nishio
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B87.
https://doi.org/10.1158/1535-7163.TARG-15-B87
Published: 01 December 2015
View article titled, Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors
Journal Articles

Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer

Shigehiro Yagishita, Yu Fujita, Satoru Kitazono, Ryo Ko, Yusuke Nakadate, Takeshi Sawada, Yuka Kitamura, Tatsu Shimoyama, Yoshiharu Maeda, Fumiyuki Takahashi, Kazuhisa Takahashi, Tomohide Tamura, Fumiaki Koizumi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (6): 1414–1423.
https://doi.org/10.1158/1535-7163.MCT-14-0625
Published: 04 June 2015
View article titled, Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
Open the PDF for Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.

Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Hiroshi Wakui, Shinji Nakamichi, Hidenori Mizugaki, Satoru Kitazono, Hironori Kanda, Kohei Suzuki, Shiro Akinaga, Tomohide Tamura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C68.
https://doi.org/10.1158/1535-7163.TARG-13-C68
Published: 01 November 2013
View article titled, Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.